May 28, 2013
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
| Attention: | Jeffrey P. Riedler, Assistant Director |
| Tabatha Akins |
| Joel Parker |
| Amy Reischauer |
| Bryan Pitko |
| Re: | Epizyme, Inc. |
Registration Statement on Form S-1 (File No. 333-187982)
Ladies and Gentlemen:
In connection with the above-captioned Registration Statement, we wish to advise that between May 21, 2013 and the date hereof 1481 copies of the Preliminary Prospectus dated May 21, 2013 were distributed as follows: 290 to prospective underwriters; 1115 to institutional investors; 0 to prospective dealers; 76 to individuals; 0 to rating agencies and 0 to others.
We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
We hereby join in the request of the registrant that the effectiveness of the above-captioned Registration Statement, as amended, be accelerated to 4:00 p.m. Eastern Time, on Thursday, May 30, 2013 or as soon thereafter as practicable.
[signature page follows]
Very truly yours,
Citigroup Global Markets Inc. Cowen and Company, LLC Leerink Swann LLC As representatives of the Prospective Underwriters
By: Citigroup Global Markets Inc. | ||
| By: | /s/ Brian Gleason | |
Name: Brian Gleason Title: Director | ||
| By: Cowen and Company, LLC | ||
| By: | /s/ Grant Miller | |
Name: Grant Miller Title: Managing Director, Head of Equity Capital Markets | ||
By: Leerink Swann LLC | ||
| By: | /s/ Daniel Dubin | |
Name: Daniel Dubin Title: Vice Chairman | ||